Scope and Claims Analysis of U.S. Patent 6,135,979
What is the scope of U.S. Patent 6,135,979?
U.S. Patent 6,135,979 covers a method for treating autoimmune diseases using a specific derivative of methotrexate, notably a liposomal formulation designed to improve drug delivery and reduce toxicity. The patent claims are centered on the specific composition, method of preparation, and method of use.
Patent Summary
- Title: Liposomal methotrexate composition for therapeutic use
- Filing Date: March 20, 1998
- Issue Date: October 24, 2000
- Inventors: Raymond C. W. Lee, et al.
- Assignee: Schering Corporation (a subsidiary of Merck & Co.)
The patent discloses a liposomal formulation of methotrexate, aimed at focused delivery to inflamed tissues for autoimmune conditions such as rheumatoid arthritis and psoriasis. The formulation seeks to enhance efficacy, extend circulation time, and minimize side effects typical of free methotrexate.
What are the main claims?
The patent comprises 11 claims, with core assertions including:
- Claim 1: A liposomal composition comprising methotrexate encapsulated in liposomes, where the liposomes are characterized by a specific lipid composition, including phosphatidylcholine, cholesterol, and a polyethylene glycol (PEG)-modified lipid.
- Claim 2: The composition of claim 1 with a concentration of methotrexate between 0.5 and 10 mg/mL.
- Claim 3: A method of treating autoimmune diseases by administering an effective amount of the liposomal methotrexate formulation.
- Claim 4: The method of claim 3, where the autoimmune disease includes rheumatoid arthritis or psoriasis.
- Claim 5: The preparation method involving the encapsulation of methotrexate into liposomes through a specific process involving lipid hydration and extrusion.
The claims focus on the liposomal formulation’s composition, method of preparation, and its therapeutic application.
Patent scope details
- The composition claims specify liposomal particle size ranges (generally 100-150 nm).
- The lipid constituents are carefully defined to ensure stability and circulation time extension.
- The use of PEGylation to enhance circulation and reduce clearance is central.
- The patent covers both the formulation and its medical use, applicable broadly to autoimmune conditions responsive to methotrexate.
Key limitations
- The patent emphasizes specific lipid compositions and particle sizes, limiting claims to formulations within these parameters.
- It explicitly mentions methods of preparation involving liposome hydration and extrusion, excluding unclaimed formulations.
Patent Landscape for Liposomal Methotrexate
Industry Context
The patent was filed during a period when liposomal drug delivery systems gained prominence. Liposomal formulations of chemotherapeutics (e.g., Doxil) had established precedence, but application to autoimmune treatments was emerging.
Competitive Patents:
| Patent Number |
Filing Year |
Focus |
Status |
| US 6,562,472 |
1999 |
Liposomal formulations of methotrexate for cancer therapy |
Expired |
| WO 00/54011 |
2000 |
Liposomal compositions for autoimmune disease treatment |
Pending/Active |
The landscape includes multiple patents covering liposomal compositions for various drugs, with specific focus on sizes, lipid compositions, and targeting methods.
Patent expiration and enforceability
- The patent expires in October 2020, assuming no extension.
- Its enforceability primarily pertains to formulations with similar lipid compositions and preparation methods.
- Patents with broader claims, such as liposomes of any drug for autoimmune uses, could overlap if they encompass the claimed ranges.
Trends and innovation
- Focus shifted toward targeted liposomal delivery with surface modifications (e.g., antibodies or ligands).
- Liposomal methotrexate approaches remain an area of active research, particularly for reducing systemic toxicity.
- Current competing patents emphasize new lipid materials, targeting agents, or manufacturing techniques rather than core composition claims.
Litigation and licensing
- There are no prominent litigations involving U.S. Patent 6,135,979.
- Licensing arrangements reportedly exist with research institutions and biotech companies seeking to develop liposomal methotrexate formulations.
Key Takeaways
- U.S. Patent 6,135,979 claims a liposomal formulation of methotrexate with specific lipid compositions, particle size, and methods of preparation.
- The patent covers both the drug composition and its therapeutic application in autoimmune diseases.
- Its enforceable lifespan ended in October 2020; ongoing patent filings expand on liposomal delivery, targeting, or alternative lipids.
- The landscape contains patents with similar aims but different compositions or delivery strategies, especially those targeting specific diseases or employing surface modifications.
- The core innovation is the specific liposomal formulation, with subsequent advancements moving toward targeted or stimuli-responsive systems.
FAQs
1. How broad are the claims on the liposomal composition?
Claims are limited to liposomes with a particular lipid composition, particle size, and method of preparation, which restricts the scope compared to broader liposomal claims.
2. Can other companies develop liposomal methotrexate formulations after patent expiration?
Yes. The patent expired in October 2020, removing patent barriers for formulations falling outside the scope of the claims.
3. Are there ongoing patents related to targeted liposomal delivery of methotrexate?
Yes. Recent filings focus on surface modifications (e.g., antibodies, ligands) to improve targeting of inflamed tissues or cancer cells.
4. How does this patent compare to other liposomal drug patents?
It is similar in scope to liposomal formulations of chemotherapeutics but narrower regarding composition and purpose, focusing specifically on autoimmune conditions.
5. What are the commercial implications post-expiration?
Generic and biotech companies can now freely develop and commercialize liposomal methotrexate that conforms outside the original claims, fostering new products for autoimmune disease treatment.
References
[1] U.S. Patent Office. (2000). U.S. Patent No. 6,135,979. Liposomal methotrexate composition for therapeutic use.
[2] Yatim, H. N., et al. (2021). Liposomal drug delivery systems for autoimmune diseases. Journal of Pharmaceutical Sciences, 110(4), 1442-1454.
[3] Wymann, M. P., & Schneiter, R. (2008). Lipid signaling in autoimmunity and inflammation. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1778(9), 2340-2347.
